Literature DB >> 29644669

Carcinoma of the Ovary.

Apm Heintz, F Odicino, P Maisonneuve, M A Quinn, J L Benedet, W T Creasman, Hys Ngan, S Pecorelli, U Beller.   

Abstract

Entities:  

Year:  2006        PMID： 29644669     DOI： 10.1016/S0020-7292(06)60033-7

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN： 0020-7292            Impact factor:   3.561


× No keyword cloud information.
  17 in total

Review 1.  Fertility sparing surgery in gynecologic cancer.

Authors:  P Rema; Iqbal Ahmed
Journal:  J Obstet Gynaecol India       Date:  2014-06-03

2.  The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass.

Authors:  Martina Montagnana; Giuseppe Lippi; Orazio Ruzzenente; Valentina Bresciani; Elisa Danese; Silvia Scevarolli; Gian Luca Salvagno; Silvia Giudici; Massimo Franchi; Gian Cesare Guidi
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

Review 3.  Interferon after surgery for women with advanced (Stage II-IV) epithelial ovarian cancer.

Authors:  Aramide O Lawal; Alfred Musekiwa; Liesl Grobler
Journal:  Cochrane Database Syst Rev       Date:  2013-06-06

4.  Markers of fibroblast-rich tumor stroma and perivascular cells in serous ovarian cancer: Inter- and intra-patient heterogeneity and impact on survival.

Authors:  Sara Corvigno; G Bea A Wisman; Artur Mezheyeuski; Ate G J van der Zee; Hans W Nijman; Elisabeth Åvall-Lundqvist; Arne Östman; Hanna Dahlstrand
Journal:  Oncotarget       Date:  2016-04-05

5.  Validation of the Performance of International Ovarian Tumor Analysis (IOTA) Methods in the Diagnosis of Early Stage Ovarian Cancer in a Non-Screening Population.

Authors:  Wouter Froyman; Laure Wynants; Chiara Landolfo; Tom Bourne; Lil Valentin; Antonia Testa; Povilas Sladkevicius; Dorella Franchi; Daniela Fischerova; Luca Savelli; Ben Van Calster; Dirk Timmerman
Journal:  Diagnostics (Basel)       Date:  2017-06-02

6.  The economic burden of disease of epithelial ovarian cancer in Spain: the OvarCost study.

Authors:  Laura Delgado-Ortega; Almudena González-Domínguez; Josep María Borrás; Juan Oliva-Moreno; Eva González-Haba; Salomón Menjón; Pedro Pérez; David Vicente; Luis Cordero; Margarita Jiménez; Susana Simón; Álvaro Hidalgo-Vega; Carlota Moya-Alarcón
Journal:  Eur J Health Econ       Date:  2018-06-19

7.  Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer.

Authors:  Xuan Jiang; Weihua Li; Xiaoying Li; Huimin Bai; Zhenyu Zhang
Journal:  Cancer Manag Res       Date:  2019-05-10       Impact factor: 3.989

8.  The treatment and outcomes of early-stage epithelial ovarian cancer: have we made any progress?

Authors:  Jk Chan; K Fuh; Jy Shin; Mk Cheung; Cb Powell; L-m Chen; Ds Kapp; K Osann
Journal:  Br J Cancer       Date:  2008-03-18       Impact factor: 7.640

9.  Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer.

Authors:  Antonio González Martín; Amit M Oza; Andrew C Embleton; Jacobus Pfisterer; Jonathan A Ledermann; Eric Pujade-Lauraine; Gunnar Kristensen; Monique A Bertrand; Philip Beale; Andrés Cervantes; Emma Kent; Richard S Kaplan; Mahesh K B Parmar; Nana Scotto; Timothy J Perren
Journal:  Gynecol Oncol       Date:  2018-11-16       Impact factor: 5.482

10.  Diagnostic value of derived neutrophil-to-lymphocyte ratio in patients with ovarian cancer.

Authors:  Yang-Yang Wu; Yuan-Yuan Qin; Jin-Qiu Qin; Xuan Zhang; Fa-Quan Lin
Journal:  J Clin Lab Anal       Date:  2019-01-21       Impact factor: 2.352
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.